Article Text

other Versions

PDF
Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis
  1. A Risselada1,
  2. J Tekstra1,
  3. O Y K Teng2,
  4. P M J Welsing1,
  5. F Breedveld2,
  6. J M van Laar2,
  7. H J W J Bijlsma1
  1. 1Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands
  2. 2Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to H J W J Bijlsma, Department of Rheumatology and Clinical Immunology (F02.127), University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands; j.w.j.bijlsma{at}umcutrecht.nl

Statistics from Altmetric.com

Rituximab, an anti-CD20 antibody targeting B cells, has been approved as treatment for patients with rheumatoid arthritis (RA) failing treatment with tumour necrosis factor α (TNFα) inhibitors.1 Reports from France, Sweden and the UK stated that rituximab as second line maintenance treatment has lower treatment costs with quality-adjusted life-year (QALY) gains compared to second line TNF inhibitors.2,,4 Annual medical costs were estimated to be 31% lower for the rituximab strategy (ie, €11.444 and €16.555, respectively).2 However, these investigators used a modelling approach, since the medical and non-medical costs for patients treated with rituximab have not yet been measured.

In the present study, we analysed medical and non-medical costs of rituximab maintenance treatment for a period of 2 years. Patients were participants of a two-centre non-randomised open-label pilot study investigating the safety …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.